Solid Tumors clinical trial intelligence

A Phase 1, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of LCAR-C18S, an CAR-T Cell Therapy Targeting Claudin18.2 in Patients With Advanced Solid Tumors

A Phase 1, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of LCAR-C18S, an CAR-T Cell Therapy Targeting Claudin18.2 in Patients With Advanced Solid Tumors is a PHASE1 clinical asset sponsored by Shanghai East Hospital in Solid Tumors, Adult. SEO and diligence focus: LCAR-C18S cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Solid Tumors, Adult

An Open-label, Phase I/II Multicenter Clinical Trial of NECVAX-NEO1 in Addition to Anti-PD-1 or Anti-PD-L1 Monoclonal Antibody Therapy in Patients With Solid Tumors

An Open-label, Phase I/II Multicenter Clinical Trial of NECVAX-NEO1 in Addition to Anti-PD-1 or Anti-PD-L1 Monoclonal Antibody Therapy in Patients With Solid Tumors is a PHASE1 clinical asset sponsored by NEC Bio B.V in Solid Tumor. SEO and diligence focus: NECVAX-NEO1, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Solid Tumor

A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies is a PHASE1 clinical asset sponsored by Incyte Corporation in Solid Tumors. SEO and diligence focus: INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Solid Tumors

A Phase I, Open-label, Dose-finding Study to Assess the Safety, Tolerability and Pharmacokinetics of ISU104, a Human Monoclonal Antibody Targeting ErbB3 in Patients With Advanced Solid Tumors

ISU104, a human monoclonal antibody targeting ErbB3, is currently in a Phase I clinical trial aimed at assessing its safety, tolerability, and pharmacokinetics in patients with advanced solid tumors. The trial's dual-part design includes a dose-escalation phase to establish the recommended Phase II dose (RP2D) and a dose-expansion phase focusing on recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Given the increasing interest in targeted therapies for solid tumors, ISU104 could position ISU Abxis Co., Ltd. favorably within a competitive landscape that includes established therapies like cetuximab. The trial's outcomes may provide critical insights into the drug's efficacy and safety profile, influencing future development strategies and potential partnerships.

Matched by conditions: Solid Tumor

A Pharmacokinetic Study of Pemetrexed in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

This clinical trial, sponsored by Northwestern University, investigates the pharmacokinetics of pemetrexed disodium in patients with leptomeningeal metastases, a challenging condition with limited treatment options. The study aims to elucidate the drug's effectiveness and safety profile in this patient population, potentially positioning pemetrexed as a viable treatment for leptomeningeal metastases. Given the increasing incidence of brain metastases and leptomeningeal disease in cancer patients, successful outcomes could enhance pemetrexed's market potential. The collaboration with the National Cancer Institute (NCI) may also facilitate further research and development opportunities. Competitive implications include the need to monitor other therapies targeting similar patient populations, particularly those in late-stage development or with established market presence.

An Exploratory Basket Study on The Application of Therapeutic mRNA Vaccine Targeting FAP in Advanced Malignant Solid Tumors

The exploratory basket study sponsored by West China Hospital aims to evaluate the safety and efficacy of a therapeutic mRNA vaccine targeting FAP in combination with immune checkpoint inhibitors for patients with advanced malignant solid tumors. Given the increasing interest in mRNA-based therapies and the critical role of CAFs in tumor progression, this trial could position the sponsor favorably within the oncology market. The potential to enhance the efficacy of existing immunotherapies by targeting the tumor microenvironment may provide a competitive edge against other therapies that do not address CAFs. However, the trial is not yet recruiting, and the timeline for results will be crucial for market positioning and investor interest.

Matched by conditions: Advanced Malignant Solid Tumors

Phase I Study of CRISPR-Cas9 Mediated PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning Regimen of Paclitaxel and Cyclophosphamide in Mesothelin Positive Multiple Solid Tumors

This Phase I clinical trial, sponsored by the Chinese PLA General Hospital, investigates the safety and feasibility of CRISPR-Cas9 mediated PD-1 gene knockout in CAR-T cells targeting mesothelin-positive solid tumors, particularly pancreatic cancer, cholangiocarcinoma, and ovarian cancer. The market for CAR-T therapies is rapidly expanding, particularly in oncology, with increasing interest in personalized and genetically modified cell therapies. The trial's focus on mesothelin, a promising target in solid tumors, positions it competitively within the CAR-T landscape. However, the trial's current status is 'recruiting,' and further data on safety and efficacy will be critical for attracting potential partnerships or investments. The success of this trial could lead to significant advancements in treatment options for patients with limited responses to existing therapies, thereby enhancing the commercial viability of the asset.

A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of MAX-10181 in Patients With Advanced Solid Tumor

MAX-10181 is being developed by Maxinovel Pty., Ltd. as a potential immunotherapy for patients with advanced solid tumors lacking established standard therapies. The Phase I trial aims to establish safety, tolerability, and pharmacokinetic characteristics, which are critical for advancing to later phases. The competitive landscape includes established PD-1/L1 inhibitors, but MAX-10181 may offer a differentiated profile or mechanism. The success of this trial could position Maxinovel favorably in the oncology market, particularly if it demonstrates a favorable safety profile and efficacy in a patient population with high unmet needs. Diligence should focus on the trial's recruitment pace, safety data, and potential for combination therapies.

Matched by conditions: Solid Tumor

A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters

The Phase III trial sponsored by the Jonsson Comprehensive Cancer Center aims to evaluate the efficacy of dalteparin in preventing catheter-related complications in cancer patients undergoing chemotherapy. If successful, this study could position dalteparin as a standard preventive treatment in oncology settings, potentially expanding its market share in the anticoagulant segment. Given the high incidence of catheter-related complications in cancer patients, the commercial opportunity is significant. However, competitive products and alternative therapies in the anticoagulation market must be considered during diligence, particularly those targeting similar patient populations.

Matched by conditions: Unspecified Adult Solid Tumor, Protocol Specific

INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies (INFORM2-NivEnt)

The INFORM2-NivEnt trial is positioned to explore the efficacy of a novel combination therapy in a pediatric population with high-risk malignancies, a segment with significant unmet medical needs. The trial's focus on specific biomarkers (high mutational load, MYC(N) amplification, high TILs, and TLS) may provide a competitive edge in precision medicine, potentially leading to a differentiated therapeutic profile. Given the limited treatment options for refractory pediatric cancers, successful outcomes could facilitate market entry and establish a strong foothold in a niche yet critical market. The collaboration with University Hospital Heidelberg and the German Cancer Research Center enhances credibility and may attract further investment or partnerships.

Matched by conditions: Solid Tumor

A Phase 1/2, Open-Label, Multicenter, Non-Randomized, Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) In Subjects With Previously Treated Advanced HER2-Positive Solid Tumors

Bellicum Pharmaceuticals is advancing BPX-603, a HER2-targeted dual-switch CAR-T cell therapy, aimed at treating advanced HER2-positive solid tumors. The market for HER2-targeted therapies is significant, particularly in breast and gastric cancers, where existing therapies may have limited efficacy in heavily pre-treated populations. The suspension of the trial due to dose-limiting toxicity in a related study raises concerns regarding safety and may impact investor confidence and future funding. However, if successful, BPX-603 could provide a novel treatment option in a competitive landscape dominated by established therapies such as trastuzumab and newer agents. The potential for a differentiated safety profile through the dual-switch mechanism may enhance its market positioning.

Matched by conditions: Solid Tumor, Adult

First-in-human Phase I Dose Escalation Study Assessing Safety, Tolerability and Preliminary Efficacy of Immunomodulatory Nanoparticles

The PRECIOUS-01 trial, sponsored by Radboud University Medical Center, is exploring a novel immunotherapeutic approach using PLGA nanoparticles to deliver iNKT cell agonists and tumor antigens for patients with NY-ESO-1-positive cancers. Given the prevalence of NY-ESO-1 expression in various malignancies (25-30% in advanced cancers), this asset targets a significant patient population with unmet medical needs. The trial's focus on safety, tolerability, and preliminary efficacy positions it strategically within the competitive landscape of immuno-oncology, where novel delivery systems and combination therapies are increasingly sought after. Successful outcomes could lead to further development and potential partnerships or licensing opportunities, particularly in the context of expanding immunotherapy portfolios.

Matched by conditions: Advanced Solid Tumor

A Single-center, Open-label, Single-arm Clinical Study of the Safety and Efficacy of KD-496 CAR-T Therapy in Advanced NKG2DL+/CLDN18.2+ Solid Tumors

The KD-496 CAR-T therapy targets advanced solid tumors expressing NKG2DL and CLDN18.2, specifically gastric and pancreatic cancers. Given the limited treatment options for patients who have failed standard therapies, this asset addresses a significant unmet need in oncology. The competitive landscape includes other CAR-T therapies and emerging treatments targeting similar tumor antigens. Successful outcomes could position KD-496 favorably in a niche market, potentially leading to partnerships or acquisition interest from larger biopharma companies. Diligence should focus on regulatory pathways, manufacturing scalability, and the evolving landscape of CAR-T therapies in solid tumors.

Matched by conditions: Solid Tumor

Evaluation of Safety, Tolerability, and Pharmacokinetics of KD6001 in Patients With Advanced Solid Tumours - Phase I Clinical Study

KD6001 is being evaluated for its safety, tolerability, and pharmacokinetics in patients with advanced solid tumors, particularly those who have failed standard treatments. The market for advanced solid tumor therapies is significant, with increasing demand for innovative treatments, especially in oncology. Given the competitive landscape, where numerous therapies are vying for approval, KD6001's unique profile and the results of this trial could position Shanghai Kanda Biotechnology Co., Ltd. favorably. Diligence should focus on the competitive advantages of KD6001, potential partnerships for further development, and the regulatory pathway ahead.

Matched by conditions: Solid Tumor

A Phase 1, Open-Label, Non-Randomized, Dose-Finding, Safety and Tolerability Study of Orally Administered Teysuno (S-1) in Combination With Epirubicin and Oxaliplatin in Patients With Advanced Solid Tumors

Disphar International B.V. is exploring the combination of Teysuno (S-1), a known oral chemotherapy agent, with epirubicin and oxaliplatin in patients with advanced solid tumors. The Phase 1 trial aims to establish the maximum tolerated dose (MTD) and assess safety and tolerability. Given the lack of established curative therapies for advanced solid tumors, this combination therapy could address a significant unmet medical need. The competitive landscape includes existing therapies for advanced solid tumors, but the unique oral formulation of S-1 may provide a differentiated offering. Diligence should focus on the safety profile and potential market acceptance of this combination therapy, especially in regions where oral chemotherapy is preferred.

Matched by conditions: Patients With Advanced or Metastatic Solid Tumors

An Open-label, Dose Escalation and Dose Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of STI-7349 in Subjects With Advanced Solid Tumors

STI-7349, developed by The Fourth Affiliated Hospital of Zhejiang University School of Medicine, is currently in a Phase 1/2 clinical trial targeting advanced solid tumors. The dual approach of evaluating STI-7349 both as a monotherapy and in combination with established immunotherapies like Pembrolizumab positions it competitively in the oncology market, particularly in the context of increasing demand for innovative treatments in solid tumors. The trial's design includes a rapid titration and traditional 3 + 3 design, which may facilitate quicker dose determination and patient enrollment. Given the growing landscape of immuno-oncology, successful outcomes could enhance market positioning and attract partnerships or acquisition interest from larger biopharma entities.

Phase I and Pharmacokinetics Study to Determine the Safety of BIBX 1382 in Patients With a Solid Tumor on a Continuous Daily Oral Administration Schedule and After Single Oral and Intravenous Doses

BIBX 1382 is currently undergoing a Phase I clinical trial aimed at assessing its safety and pharmacokinetics in patients with solid tumors. The trial is sponsored by the European Organisation for Research and Treatment of Cancer (EORTC) and is designed to determine the maximum tolerated dose and document any antitumor activity. Given the competitive landscape of oncology therapeutics, particularly for solid tumors, successful outcomes in this trial could position BIBX 1382 favorably in a market characterized by high demand for novel treatments. However, the trial's current status is suspended, which may pose challenges for future development and investor confidence.

Matched by conditions: Unspecified Adult Solid Tumor, Protocol Specific

Phase Ⅰ Study of EGFR Targeted TGFβR-KO CAR T Cells in the Treatment of Previously Treated Advanced EGFR-positive Solid Tumors

Phase Ⅰ Study of EGFR Targeted TGFβR-KO CAR T Cells in the Treatment of Previously Treated Advanced EGFR-positive Solid Tumors is a PHASE1 clinical asset sponsored by Chinese PLA General Hospital in Solid Tumor, Adult, EGFR Overexpression. SEO and diligence focus: TGFβR-KO CAR-EGFR T Cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Solid Tumor, Adult

A Phase I Clinical Trial of Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors

This Phase I clinical trial, sponsored by Memorial Sloan Kettering Cancer Center, focuses on the safety and dosing of autologous T cells engineered to target the MUC16ecto antigen, prevalent in approximately 70% of ovarian cancers. The trial's innovative approach combines cyclophosphamide conditioning with T cell therapy, positioning it within the growing field of CAR T-cell therapies. Given the high unmet need in recurrent ovarian cancer, successful outcomes could lead to significant market opportunities, particularly in a landscape where current treatment options are limited. Collaboration with Juno Therapeutics, a Bristol-Myers Squibb Company, may enhance development capabilities and market access. However, the competitive landscape includes other emerging therapies targeting similar pathways, necessitating ongoing diligence regarding market positioning and differentiation.

A Phase I/Ib Open-label, Multi-center, Dose Escalation Study of GWN323 (Anti-GITR) as a Single Agent and in Combination With PDR001 (Anti-PD-1) in Patients With Advanced Solid Tumors and Lymphomas

The Phase I/Ib study of GWN323 (anti-GITR) in combination with PDR001 (anti-PD-1) represents a strategic initiative by Novartis Pharmaceuticals to enhance the therapeutic landscape for patients with advanced solid tumors and lymphomas. Given the increasing interest in immuno-oncology therapies, this dual-target approach may provide a competitive edge in a crowded market. The trial's completion and subsequent data analysis will be critical in determining the viability of GWN323 as a standalone treatment and in combination therapy, potentially positioning Novartis favorably against competitors in the immunotherapy space. The enrollment of approximately 264 patients indicates a significant investment in understanding the safety and efficacy of these agents, which could lead to future regulatory submissions and market entry.

Matched by conditions: Solid Tumors